Post-exposure vaccination with the vaccine candidate Bacillus Calmette-Guérin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis

Microbes Infect. 2016 May;18(5):364-8. doi: 10.1016/j.micinf.2016.03.005. Epub 2016 Mar 17.

Abstract

The tuberculosis vaccine BCG ΔureC::hly is the most advanced BCG replacement candidate in phase II clinical development. Here we assess the protective capacity of the construct administered to mice as homologous prime-boost vaccine prior Mycobacterium tuberculosis infection and as post-exposure vaccine. Multiple immunization did not improve the superior protection of BCG ΔureC::hly over BCG. Animals with subclinical tuberculosis were better protected when vaccinated with BCG ΔureC::hly as compared to BCG. Our findings suggest further consideration of BCG ΔureC::hly as post-exposure vaccine.

Keywords: BCG; Post-exposure vaccination; VPM1002.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Asymptomatic Infections*
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / immunology*
  • Bacterial Proteins / genetics*
  • Female
  • Gene Deletion*
  • Mice, Inbred BALB C
  • Mycobacterium bovis / genetics
  • Mycobacterium bovis / immunology*
  • Post-Exposure Prophylaxis / methods*
  • Treatment Outcome
  • Tuberculosis / immunology
  • Tuberculosis / prevention & control*

Substances

  • BCG Vaccine
  • Bacterial Proteins